Skip to main content

Table 4 Patient treatment characteristics and laboratory data as reported in CROWNWeb, by recovery status

From: Predictors of kidney function recovery among incident ESRD patients

Variablea All Patients With Recovery (n = 16,930) Patients Without Recovery (n = 355,457) P-value
N Mean (SD) or Proportion N Mean (SD) or Proportion N Mean (SD) or Proportion
Albumin (g/dL) 353,182 3.5 (0.5) 16,012 3.4 (0.5) 337,170 3.5 (0.5) < 0.001
Calcium (mg/dL) 355,196 8.8 (0.6) 16,226 8.9 (0.6) 338,970 8.8 (0.6) < 0.001
Hemoglobin (g/dL) 357,569 10.4 (1.0) 16,365 10.3 (1.2) 341,204 10.4 (1.0) < 0.001
ESA monthly dose (units) 299,143 43,949 (40196) 12,284 39,733 (40193) 286,859 44,130 (40187) < 0.001
Ferritin 342,910 460 (328) 15,232 533 (373) 327,678 458 (325) < 0.001
Iron % saturation 349,400 24.1 (8.8) 15,769 23 (10.1) 333,631 24.1 (8.8) < 0.001
IV Iron administration
 Yes 212,999 59.7% 8534 52.7% 204,465 60.0% < 0.001
 No 144,016 40.3% 7647 47.3% 136,369 40.0%  
Phosphorus (mg/dL) 356,401 4.8 (1.2) 16,288 4.1 (1.0) 340,113 4.8 (1.2) < 0.001
Parathyroid Hormone (pg/mL) 83,940 367 (314) 3755 221 (187) 80,185 374 (317) < 0.001
Vascular Access Type        < 0.001
 AVF/AVG 87,996 24.3% 915 5.5% 87,081 25.2%  
 Catheter 255,931 70.8% 14,817 89.4% 241,114 69.9%  
 Other 17,819 4.9% 837 5.1% 16,982 4.9%  
Treatment time per session (minutes) 335,737 223 (28) 15,996 219 (29) 319,741 223 (28) < 0.001
Single pool Kt/V 353,328 1.5 (0.3) 16,101 1.5 (0.3) 337,227 1.5 (0.3) < 0.001
Normalized protein catabolic rate (g/kg/d) 270,580 0.8 (0.2) 10,943 0.70 (0.2) 259,637 0.8 (0.2) < 0.001
Pre-HD weight (kg) 335,856 84.3 (23.9) 16,004 85.8 (24.7) 319,852 84.2 (23.8) < 0.001
Post-HD weight (kg) 335,855 82.3 (23.5) 16,004 84.2 (24.3) 319,851 82.2 (23.4) < 0.001
Mean ultrafiltration rate (ml/kg/hr) 372,271 6.9 (3.1) 16,920 5.4 (3.5) 355,351 7.0 (3.1) < 0.001
Quintile of ultrafiltration rate        < 0.001
 1st (lowest) (<=4.3) 74,454 20.0% 6779 40.1% 67,675 19.0%  
 2nd (> 4.3–5.9) 74,454 20.0% 3369 19.9% 71,085 20.0%  
 3rd (> 5.9–7.3) 74,455 20.0% 2558 15.1% 71,897 20.2%  
 4th (> 7.3–9.1) 74,454 20.0% 2117 12.5% 72,337 20.4%  
 5th (> 9.1) 74,454 20.0% 2097 12.4%% 72,357 20.4%  
  1. ESA Erythropoiesis-stimulating agent (includes all forms of ESA but predominantly epoeitin alfa during study period), AVF Arteriovenous fistula, AVG Arteriovenous graft, HD Hemodialysis. Note: collection of parathyroid hormone data in CROWNWeb ceased in April 2014
  2. aLaboratory values are reported as the mean (SD) for continuous variables, and as a proportion for categorical variables. Data is aggregated for the first 3 months after dialysis initiation